New drug shows promise in treating pancreatic cancer
新藥展現治療胰臟癌的前景
更新於: 2026年8月1日 上午12:30
Pancreatic cancer has long been one of the most challenging diseases to treat, but a medical breakthrough is offering new hope.
胰臟癌長期以來一直是最難治療的疾病之一，但一項醫學突破帶來了新的希望。
A drug called daraxonrasib, formerly known as RMC-6236, is being hailed by oncologists as a game-changer.
一種名為 daraxonrasib 的藥物（前身為 RMC-6236）被腫瘤科醫師譽為具有突破性（game-changer）的變革。
For decades, the KRAS gene mutation, which drives about 90% of pancreatic cancers, was considered 'undruggable' because the protein lacked a binding site for traditional medicine.
數十年來，驅動約 90% 胰臟癌的 KRAS 基因突變因該蛋白質缺乏傳統藥物的結合位點，而被認為是「不可成藥」（undruggable）的。
Daraxonrasib overcomes this by acting as a 'molecular glue,' linking to a helper protein to block KRAS growth signals.
Daraxonrasib 通過作為一種「分子膠」（molecular glue），連接輔助蛋白質以阻斷 KRAS 生長訊號，從而克服了這一點。
In the RASolute 302 trial, patients using the drug saw their median survival time double compared to standard chemotherapy, increasing from 6.7 to 13.2 months.
在 RASolute 302 試驗中，使用該藥物的患者中位存活時間較標準化療翻了一倍，從 6.7 個月延長至 13.2 個月。
While currently awaiting final FDA approval, the drug represents a major paradigm shift.
儘管目前正等待 FDA 的最終批准，但該藥物代表了一個重大的典範轉移。
However, ongoing research is exploring its use in other cancers, including lung and colorectal tumors, marking a significant step forward in oncology.
不過，目前的研究正在探索其在包括肺癌和結腸直腸癌在內的其他癌症中的應用，標誌著腫瘤學向前邁出了重要的一步。
